| Biological Activity |
Whey proteins with reported Activity* |
Comments |
| Antimicrobial Action/wound healing |
a) Lactoferrin, lactoperoxidase,
lysozyme b) Lactoferricin (pepsin derived peptide from lactoferrin) |
a) Supported by both invitro and some
invivo studies. The proteins are being used applied commercially; combinations are
synergistic. B )More antimicrobial than lactoferrin. Active component
produced through biotechnology. |
| Passive immunity - disease protection |
Whey protein concentrates, colostrum
derived immunoglobulin concentrates; immunoglobulins |
Have been proven effective in calves
and pigs. Hyper-immunization increases specific Ig activity for some not all bacterial
antigens. |
| Bifidobacteria growth factor/control
of intestinal microflora |
casein glycomacropeptide |
Has been used commercially. Confirmed
in trials with infants and one trial on human adults. Oligosaccharide portion considered
most active. Oligoscacchide growth factors also provided by soybeans and Jerusalem
artichokes |
| Anti-viral activity |
a) lactoferrin b)
lactoferricin
c) Whey protein concentrates, |
a) Supported by 3 invitro studies, one
showing the antiviral property being independent of iron binding b)
Supported by single study
c) Only limited studies support this claim |
| Anti-cancer activity |
whey protein concentrates |
Fairly strong support based on cell
culture studies and invivo in mice and rats |
| Gut microflora control |
Whey Protein concentrates |
|
| Immunomodulating activity - |
a) Whey protein concentrates b)
Lactoferrin
c) Casein glycomacropeptide
d) a -lactalbumin |
a) Based on invitro studies and
several invivo studies in mice- enhanced humoral antibody responses b)
Supported by cell culture studies and invivo studies with experimental animals
c) Five reports supporting this activity - with different specific functions
d) Based on a single report |
| Bacterial antitoxin activity |
a) Lactoferrin b)
Casein glycomacropeptide
c) GMP derived peptides
d)Glycated-b -lactoglobulin and glycated a -lactalbumin |
a) Multiple reports confirming
activity b) Supported by single report
c) Supported by several studies
d) Support only by a single invitro study
Supported by only on report - not confirmed |
| Promotion of growth of some animal
cells |
a) lactoferrin |
a) One invivo study and 2 patents
claiming application |
| Platelet binding (anti thrombic
activity) |
a) lactoferrin b)
GMP derived peptide |
a )Limited evidence to support this
claim b) 3 studies in support |
| Anti-inflammatory |
lactoferrin |
Based on single 1996 report |
| Anti-hypertensive |
GMP derived peptide (108-110) |
Supported by two reports |
| Control of cellular glutathione levels |
Whey protein concentrate |
Based on limited studies. Considered
to possibly serve as an antioxidant and in the repair of DNA. Requires further
confirmation |
| Diet suppressant -reduction in gastric
secretion |
Casein glycomacropeptide |
Based primarily on studies with dogs,
primarily studied by a single research group. |
| Control of PKU |
casein glycomacropeptide |
Is aromatic amino acid free, but not
known to have been used for control of PKU |
| Iron transport |
lactoferrin |
Long accepted, but now being
challenged - requires clarification |
| Opiod Effect (reduction in heart rate
and respiration |
Peptides derived from GMP, b -lactoglobulin, a -lactalbumin |
Limited evidence to support this
effect, primarily in experimental animals |